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mine the impact of parameter uncertainty. Results: With universal vaccination 
at a cost per dose of Php 624 for PCV10 and Php 700 for PCV13, both PCVs are cost-
effective compared to no vaccination given the ceiling threshold of Php 120,000 per 
QALY gained, yielding ICERs of Php 68,182 and Php 54,510 for PCV10 and PCV13, 
respectively. Partial vaccination of 25% of the birth cohort resulted in significantly 
higher ICER values (Php 112,640 for PCV10 and Php 84,654 for PCV13) due to loss 
of herd protection. The budget impact analysis reveals that universal vaccination 
would cost Php 3.87 billion to 4.34 billion per annual, or 1.6 to 1.8 times the budget 
of the current national vaccination program. ConClusions: The inclusion of PCV 
in the national immunization program is recommended. PCV13 achieved better 
value for money compared to PCV10. However, the affordability and sustainability of 
PCV implementation over the long-term should be considered by decision makers.
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objeCtives: Primary care physicians (PCPs) play a key role in France in the prescrip-
tion and administration of recommended vaccines. Uneven vaccination coverage in 
vulnerable populations appeals for specific interventions to be designed to address 
existing barriers faced by targeted groups of PCPs. The ‘Determinant of Intentions 
of VAccination’ (DIVA©) questionnaire was developed to assess PCPs’ attitudes and 
beliefs toward vaccination. The objectives of the study were to define the scoring rules 
and to assess the measurement properties of the DIVA questionnaire. Methods: 
A cross-sectional study was conducted in France with PCPs to define the scoring 
of DIVA and to assess its measurement properties. PCPs had to complete the DIVA 
questionnaire in to any of the six vaccine-preventable diseases (VPD) they were ran-
domly assigned (measles, pertussis, pneumococcus infection, seasonal influenza, 
HVP infection and tetanus). Internal consistency reliability and known groups valid-
ity were assessed. Results: DIVA was completed by 1,069 PCPs (mean age 48; 58% 
male), with very good quality of completion (90% of questionnaires with no missing 
item). One redundant item was removed from the questionnaire. The final DIVA was 
composed of 55 items, grouped into six thematic domains covering disease, vaccine, 
information, organisation, consultation, and PCP experience, and one domain assess-
ing PCP’s engagement. The Engagement score showed very good internal consist-
ency reliability across the six VPD (0.80≤ Cronbach’s alpha< 0.90). The Rasch model 
validated the number, content and modalities of items of the Engagement domain. 
The six thematic scores showed overall good known groups validity. ConClusions: 
DIVA is a valid and reliable measure to assess PCPs’ engagement toward vaccination, 
as well as the specific barriers they face in various VPD. DIVA might help to define 
specific interventions aimed at improving PCPs vaccination activity, and can serve as 
an outcome measure to assess the impact of such interventions.
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objeCtives: Follow-up of critical laboratory results can present a challenge in 
resource limited settings due to high patient volumes, overstretched human 
resources and no systematic communication from the laboratory. An audit con-
ducted in 2013 in a large outpatient HIV-center revealed that < 50% of critical 
results were acted upon within 24 hours. Our objective is to describe the impact 
of the new developed guidelines on reducing mortality of patients with critical 
results. Methods: Results must be immediately communicated by the labora-
tory to a physician via an “on-call phone”; patients should be contacted and asked 
to return to the clinic. In addition all critical laboratory results were reviewed 
and tagged by Quality Management staff. Design: retrospective survey of all files 
of patients who had in 2014 at least one of the following: Hb < 5.5g/dl, creati-
nine > 3.4mg/dl, positive serum Cryptococcus-Antigen (Crag). Clinician’s actions 
were categorized and described. Turnaround time was determined and incidence 
of mortality between 2013 and 2014 compared. Results: During 2014, 5,907 
patients had any laboratory test done. Hb < 5.5g/dl: 36(0.6%) patients. Action taken: 
blood transfusion 17/36 (47%), heamatinics14/36(39%) and 2/36(6%) dewormed. 
Creatinine > 3.4mg/dl: 64/3291(1.9%) patients. Action taken: antiretroviral treat-
ment regimen switched 43/64(67%), 2/64(3%) stopped, 12/64(19%) referral to the 
renal unit. Positive serum-Crag 17/464(3.7%). Action taken: 12/17(71%) started on 
fluconazole, 5/17(29%) were already on treatment. Turnaround time for Hb and 
serum crag was < 1 day, creatinine 13.3 days. From 2013 and 2014 the mortality 
decreased in patients with Hb< 5.5g/dl from 27.9 to 2.8%, with creatinine> 3.4mg/dl 
from 32.9 to 3.1% and with positive serum-Crag from 36.4 to 23.5%. ConClusions: 
Critical results monitoring system greatly improves patient turnaround time, 
and reduces mortality through timely communication and patients follow up. 
We believe our system could serve as a role model for similar programs in Sub-
Saharan Africa to improve quality of care.
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in specialists compared to GPs (23,5% vs 14,0% respectively, P< 0,04, CI 1,05-3,38). On 
contrary, more specialists chose to never discuss antibiotic treatment with patients 
compared to GPs (19,1% vs 7,2%, P< 0,001, CI 1,46-6,2) and there were more GPs 
that always discussed antibiotic treatment with patients compared to specialists 
(15,8% vs 5,9%, P< 0,01, CI 0,14-0,78). Patients’ co-payment seems to be more sensi-
tive issue for GPs compared to specialists since 29% of GPs considered co-payment 
all the time or most of the time when choosing ATB compared to specialists (18,4%, 
P= NS). ConClusions: This survey revealed that both GPs and specialists are 
aware of the importance of antimicrobial resistance and demonstrated differences 
between specialties with respect to antimicrobial use and knowledge. Antimicrobial 
education is needed but may be more effective if it is tailored to specific specialties.
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objeCtives: Generate research questions through studies published and financed 
by government or public research intuitions is an important tool in management 
of the public health system. While there are a growing number of papers, guide-
lines and funding in research, there are specific needs for different countries that 
need answers. Thus, researching gaps within the needs of each country contrib-
utes to optimization of public spending and guidance for promoting effective 
research. Methods: We conducted a search in the Brazilian database “Pesquisa 
Saúde” as in the international databases Pubmed Health; Cochrane Library and 
Prospero. For the international databases, we used the terms: “ Drug Resistance, 
Microbial”, “Antimicrobial Drug Resistances” and “Resistance, Antibiotic” with meta-
analyzes within 10 years cutouts. Results: A total of 212 trials were identified. 
Those trials were scored as 1 for the most important and 2 for least significant, 
according to local priorities. We obtained 107 studies with a score 1. These studies 
were carefully analyzed to guide which unanswered questions should develop in 
new researches. ConClusions: Clinical and epidemiological characterization of 
gaps has been identified on mortality and morbidity, related with antimicrobial 
prescribing patterns. We also identified gaps in prevention and control of prescrip-
tion practices, colonization time in patients and detection of Mycobacterium tuber-
culosis strains. About economic impact and cost of RAM for the health system we 
identified gaps in hospital infections. The gaps identified will subside the financing 
of new studies by DECIT / MS in order to contribute to the national plan for preven-
tion and combating RAM which is part of the WHO global plan.
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objeCtives: This article describes the epidemiological features of spread of HIV 
infection in the Republic of Kazakhstan. We have examined gender-specific of HIV- 
infection in the Republic of Kazakhstan. As of December 31, 2013, 19 905 cases of 
HIV- infection have been registered in the country, 1933 persons of which were 
tested positive for AIDS, 1431 persons died. Methods: All the cases of HIV- trans-
mission in Kazakhstan for 26 years (1987-2013) have been analyzed. Statistical data 
was processed by means of BIOSTAT program. Extensive, crude, age indexes were 
calculated based on the general methods of health statistics Results: The preva-
lence of HIV in Kazakhstan is 86,5 out of 100 thousand people (0,090/0000), while 
the age group is people from 15 years old and older- 0,140/0000. Unequal distribu-
tion of the cases of HIV-infection on the territory of Kazakhstan is being observed. 
Accroding to the cumulative figures (1987 – 2013), 60,9% of HIV-positive people got 
an infection parentally (during the intravenous injection of narcotic substances), 
while the ratio of the persons with sexually transmitted infection is 34%. In 2013, the 
sexual transmition (heterosexual) of HIV-infection constitued 59,8%, while parental 
transmission made 33,5%. The highest ratio among the registered cases falls within 
the age group of 20 to 39 years old, i.e. 70,7%. Over the past years, the proportion of 
women in the disease detection structure is 44,1% (in 2011 - 39,6%; in 2012- 41,9%), 
the proportion of men among the detected cases is decreasing - 55,9% (in 2011 - 
60,4%; in 2012 - 58,1%). ConClusions: Epidemiological analysis shows that the 
number of HIV-positive is increasing, the largest part of them are young people at 
the age of 20 to 39 years old. The ratio of HIV-positive women has increased, the 
infection transmission route has changed- the heterosexual transmission is taking 
the leading position.
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objeCtives: The objective of this study is to assess the value for money of introduc-
ing pneumococcal conjugate vaccines as part of the immunization program in a 
lower-middle income country, the Philippines, which is not eligible for GAVI support 
and lower vaccine prices. It also includes the newest clinical evidence evaluating 
the efficacy of PCV10, which is lacking in other previous studies. Methods: A 
cost-utility analysis was conducted. A Markov simulation model was constructed 
to examine the costs and consequences of PCV10 and PCV13 against the current 
scenario of no PCV vaccination for a lifetime horizon. A health system perspective 
was employed to explore different funding schemes, which include universal or 
partial vaccination coverage subsidized by the government. Results were presented 
as incremental cost-effectiveness ratios (ICERs) in Philippine peso (Php) per QALY 
gained (1 USD = 44.20 Php). Probabilistic sensitivity analysis was performed to deter-
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compared to those without ICS and statins. However, analyses using combined 
medication categories revealed that only adults with statin use in combination with 
antidepressants and ICS or ICS alone were more likely to have new-onset diabetes. 
Instrumental variable adjusted regression which controlled for selection bias in 
statin use revealed no significant association between statin use and new-onset dia-
betes. ConClusions: Our study results suggest that multiple medication use (anti-
depressants, ICS and statins) was not associated with new-onset diabetes. However, 
as individuals with COPD are at higher risk of developing new-onset diabetes due to 
shared risk factors, further research with longer follow-up and randomized design 
is require to evaluate the safety of these medications.
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objeCtives: The aim of the study was to explore the association of waist circum-
ference with microvascular complications in Malaysian patients with type 2 diabe-
tes. Methods: We utilised data of type 2 diabetes patients followed up in Malaysian 
public sector primary care clinics contained in the National Diabetes Registry in 
the year 2012. Variables of interest were the presence of microvascular complica-
tions, namely nephropathy and retinopathy. Multiple logistic regression was used 
to explore the association between presence of microvascular complications and 
waist circumference, which was adjusted for age, sex, duration of diabetes, systolic 
blood pressure, insulin use, total cholesterol and HbA1c. Results: A total of 114,719 
patients with type 2 diabetes were included in the study. The mean age of patients 
was 59.8 years (SD: 11.2) with mean duration of diabetes of 6.8 years (SD: 5.1). Male 
patients comprised 39.9% of the sample population and 83.5% of the patients were 
overweight with BMI ≥ 23 kg/m2. Nephropathy and retinopathy was present in 9.1% 
and 7.9% of patients respectively. The mean waist circumference was 94.1 cm (SD: 
11.8) for males and 90.8 cm (SD: 11.8) for females; while 78.4% of the patients had waist 
circumference above the cut off (≥ 90 cm for men and ≥ 80 cm for women). Larger 
waist circumference was found to be significantly associated with nephropathy (adj. 
OR 1.005; p-value< 0.001; 95% CI: 1.003–1.008) after adjusting for confounding factors. 
However, waist circumference was not significantly associated with retinopathy (adj. 
OR 0.998; p= 0.209; 95% CI: 0.996–1.001). ConClusions: Analysis showed that patients 
with higher waist circumference were more likely to have nephropathy than patients 
with lower waist circumference. The analysis also showed that waist circumference 
was not associated with retinopathy in the study population.
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objeCtives: The relationship between glycaemic burden and micro- and macrovascu-
lar complications among patients with type 2 diabetes mellitus (T2DM) was investigated 
using real-world data. Methods: T2DM patients aged 40 to 84 years and receiving 
antihyperglycaemic agents (AHAs) during the analysis period (2004-2013) were selected 
from the PHARMO Database Network. All HbA1c measurements between the first AHA 
prescription (index date) recorded and end of follow-up (i.e., end of database regis-
tration, death, or end of study period, whichever occurred first) were used to assess 
glycaemic burden. Glycaemic burden was defined based on the extent and duration 
that HbA1c values exceeded a threshold of 7% (53 mmol/mol) and was expressed as gly-
caemic burden years (GBY). The relationship between GBY and microvascular (includ-
ing retinopathy, diabetic foot, nephropathy) and macrovascular (including coronary 
artery disease [CAD], cerebrovascular disease) complications were analysed using a 
time-dependent Cox proportional hazards model, with glycaemic burden entered in 
each regression as a categorical variable with four levels (no burden [reference], 0-≤ 1 
GBY, > 1-≤ 3 GBY, and > 3 GBY). Results: A total of 34,153 T2DM patients were included; 
mean (±standard deviation) age at index date was 66 (±11) years and 53% were male. 
As compared to patients with no GBY, patients with GBY (0-≤ 1 GBY, > 1-≤ 3 GBY, and 
> 3 GBY) had a significantly higher risk of developing retinopathy (hazard ratio [HR]: 
1.38, 1.76, and 2.22, respectively), diabetic foot (HR: 1.08, 1.24, and 1.55, respectively), 
nephropathy (HR: 1.11, 1.16, and 1.14, respectively), and cerebrovascular disease (HR: 
1.16, 1.28, and 1.36, respectively). For CAD, a significantly higher risk was found only for 
patients with > 1-≤ 3 GBY and > 3 GBY (HR: 1.12 and 1.32, respectively). ConClusions: 
Results of this study show that GBY is an important predictor of micro- and macrovas-
cular complications and thus may be important to consider in T2DM management.
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objeCtives: A network meta-analysis (NMA) was conducted to estimate the rela-
tive efficacy and tolerability of exenatide 2mg once-weekly (EQW), a glucagon-
like peptide-1 receptor agonist (GLP-1 RA), compared to other GLP-1 RAs for the 
treatment of adult patients with type 2 diabetes mellitus (T2DM) not adequately 
controlled on metformin (MET). Methods: A systematic literature review was 
objeCtives: Before 2006 bed occupancy rates during winter periods were above 
the good management threshold (85%) in Jessa Hospital paediatric ward (Hasselt, 
Belgium), with peaks above 100%. This causes pressure on bed and people man-
agement expressed in bad QoC scores. We evaluated two methods to improve the 
scores and their investment costs. Methods: Option A is extending the number 
of paediatric beds until the unit operates under the 85% threshold during the 
whole winter season. Option B is introducing rotavirus vaccination to infants 
with high coverage in the catchment area. A hospital with 36 paediatric beds 
was selected as pilot design. Bed occupancy rates/day over a period of 6 years 
(2004-2009) were collected, including pre- and post-introduction of the vaccine 
in 2006. Estimated birth cohort was 7,000/year in the catchment area. For Option 
A total cost per year was calculated referencing to the observed pre-vaccination 
period. For Option B cost of vaccinating the birth cohort with implications on 
hospital savings was calculated applying the observed post-vaccination period. 
Total cost per year for each option was compared. Results: Option A: extend-
ing hospital ward with 4 extra beds to remain under the threshold, costs about 
€ 436,000/year and the threshold may still sometimes be exceeded. Option B: 
vaccination program in the area costs € 420,000/year, leading to a 41% reduction 
in the number of bed-days for gastro-enteritis during the winter, equivalent to 
€ 82,000/year of cost offsets. Total cost of Option B is therefore € 338,000/year with 
an overall 82% bed occupancy rate/day, being below the threshold throughout win-
ters. ConClusions: Option B with vaccination is cheaper than option A with extra 
beds. Moreover it maintains the occupancy rate below the safety threshold during 
the whole winter period, and thus guarantees better QoC scores in the pediatric 
ward.
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objeCtives: To estimate the incremental cost-effectiveness ratio (ICER) of the 
pneumococcal non-typeable Haemophilus influenzaeprotein D conjugate vaccine 
(PHiD-CV) compared to the 13-valent pneumococcal conjugate vaccine (PCV-13) in 
routine infant vaccination in Portugal. Methods: The cost-effectiveness analysis 
(CEA) is based on a Markov model simulating meningitis, bacteraemia, pneumonia 
and acute otitis media (AOM) in a Portuguese birth cohort until 10 years of age. 
CEA is performed from the National Health Service (NHS) perspective with 5% 
discounting on both costs and effects. The model has been parameterized using 
local serotype distribution, disease incidence and direct medical costs. Disutility 
weights come from international published literature and vaccine efficacy 
assumptions come from large randomized controlled trials. Model parameters 
have been validated by a panel of experts. Base case scenario assumes vaccina-
tion in a 2+1 schedule at 2, 4 and 12 months of age with 95% coverage. One-way 
and probabilistic sensitivity analyses were carried out to identify most influential 
parameters and estimate conjoint parameter uncertainty, respectively. Results: 
Assuming both vaccines have the same price, the model predicts that PHiD-CV 
is the dominant intervention resulting in a health gain of 7 Quality-Adjusted 
Life Years (QALYs) and a saving of 332,151€ over PCV-13 (ICER = -45,216€ /QALY). 
One-way sensitivity analysis shows ICER is very sensitive to efficacy against 
Streptococcus pneumoniae and Haemophilus influenzae, general practices visits 
and disutility, all related to AOM. The probabilistic sensitivity analysis confirms 
the robustness of our results with 93% of simulations showing that PHiD-CV ICER 
is below € 30,000/QALY compared to PCV-13. ConClusions: Using PHiD-CV in the 
routine vaccination program for children in Portugal could generate more health 
benefits and savings for NHS, even when considering parity price versus PCV-13. 
These savings could then be used to implement other public health measures such 
as a catch-up program to reduce inequalities in older cohorts.
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objeCtives: Multiple medication use is common among individuals with Chronic 
Obstructive Pulmonary Disease (COPD). Specifically, use of antidepressants, inhaled 
corticosteroids (ICS), and statins may place individuals with COPD at high risk for 
new-onset diabetes. We examined the relationship between use of medications 
(antidepressants, ICS, and statins) and new-onset diabetes among Medicaid ben-
eficiaries with COPD. Methods: We used a retrospective longitudinal dynamic 
cohort design using multiple years (2005-2008) of Medicaid claims of beneficiaries 
with newly diagnosed COPD (n = 15,287). We identified receipt of antidepressants, 
ICS, and statins using National Drug Codes (NDC) and new-onset diabetes using 
International Classification of Diseases-9th-Clinical Modification (250.x2) codes. 
Chi-square tests of independence and multivariate logistic regressions were used 
to examine the relationship between medication use and new-onset diabetes. 
Instrumental variable approach was used to control for selection bias in statin use. 
We conducted analysis using SAS v. 9.3 and STATA v11. Results: Among Medicaid 
beneficiaries with newly-diagnosed COPD, 6.3% had new-onset diabetes. After con-
trolling for baseline characteristics, adults with ICS (AOR: 1.23; 95% CI: 1.07, 1.47) 
and statins (AOR: 1.48; 95% CI: 1.27, 1.72) had greater risk of new-onset diabetes 
